10:35 EDT Sarepta (SRPT) jumps 5% to $42.11 after UK allows Elevidys study to continue
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta announces MHRA says ENVISION dosing may continue as planned
- Buy Rating on Sarepta Therapeutics: Valuation Disconnect and Growth Potential Highlighted by Elevidys Approval
- Sarepta price target lowered to $84 from $169 at JPMorgan
- Positive Outlook for Sarepta Therapeutics Amid Elevidys Expansion and Strategic Collaborations
- Sarepta reports positive ELEVIDYS protein expression data in young patients
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue